+390677209020 | +39 0267380552 info@direnzo.biz | sedemilano@direnzo.biz | Italian Language

EMA database update: novelties for XEVMPD and PMS, expiry dates and support for MA holders

Ema database Update

The European Medicine Agency (EMA) has introduced some important novelties for the management of drug regulatory data, starting the switch from the “eXtended EudraVigilance Medicinal Product Dictionary” (XEVMPD) database to the new “Product Management Service” (PMS).

This change is a significant step in the digitalisation of information on medicinal products and involves directly all Marketing Authorisation (MA) Holders.

What is exactly the XEVMPD database and why switching to the PMS?

For years the XEVMPD database has been a reference point for the registration and update of data on medicines in Europe.

The switch to the PMS meets a regulatory requirement on the mandatory use of a different data format, now  ISO IDMP compliant.

This improves the quality, consistency and traceability of the information , especially allowing the implementation of complex digital change initiatives, driven by EMA, such as the adoption of the Electronic product information (ePI), the adoption of the web-based Application Form and the implementation of the ESMP portal for the management of critical drug shortage during crisis or emergency.

The intent is to facilitate the exchange of information and communication to drug stakeholders, from the Competent Authorities to Pharmaceutical companies, supporting the final users, i.e. patients.

Before proceeding with the data enrichment provided for in the new system, it is essential to ensure that the migration of information from XEVMPD to PMS takes place correctly, also confirming the accuracy and consistency of the starting data.

EMA database update: deadlines and new PMS requirements 

With the introduction of the PMS, EMA has prepared a detailed calendar for the update of the information on drugs by holders, with various deadlines depending on the product type:

  • Within June 2026: update of structured manufacturer data and authorised operations (API and finished product), together with pack size data for medicines considered as critical, included in the “Union list of critical medicines”
  • Within December 2026: update of manufacturer information and authorised operations for all the other medicines considered as non critical, and therefore not included in the “Union list of critical medicines”
  • Within June 2027: update of structured data of the pack sizes for non critical medicines.

What should MA Holders do?

MA Holders have therefore the following tasks to complete:

  1. Control data migration from XEVMPD to PMS and implement any corrective actions required to correct any discrepancy
  2. Plan the data enrichment in the PMS based on the deadlines established by EMA.
  3. Cooperate internally among the various departments, such as regulatory affairs, pharmacovigilance and supply chain, to ensure that the data included in the PMS are specific and in line with the current authorisations
  4. Update their standard operating procedures (SOPs) to describe their new processes

Adopting a proactive and well-structured approach will help pharmaceutical companies to comply with the deadlines and ensure full compliance with the new regulatory requirements.

How can Di Renzo Regulatory Affairs support pharmaceutical companies?

In a time of regulatory changes and digital transformation, Di Renzo Regulatory Affairs offers full support, leading companies through every step of the PMS adaptation.

Our team of experts can assist companies in several aspects, such as:

  • Control data migration from XEVMPD to PMS
  • PMS data enrichment according to the deadlines defined by EMA
  • Staff training  on the new EMA requirements and on the timetable to comply with

Thanks to our wide experience in pharmaceutical regulatory consulting, we help companies to ensure conformity, quality and timeliness during the whole process for the update of the EMA database.

The switch from XEVMPD to PMS is an essential step in the evolution of the regulatory management of medicinal products in Europe.

Complying with the new requirements and meeting the deadlines established by EMA is crucial to maintain regulatory compliance.

With the support of Di Renzo Regulatory Affairs, companies can face this transition with trust and competence, ensuring the alignment to the new European directives and contributing to a more transparent and digital product data management.